UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 72

Sortiert nach

NOTCH1 Signalling: A key pathway for the development of high-risk chronic lymphocytic leukaemia

Frontiers in oncology, 2022-10, Vol.12, p.1019730-1019730

Edelmann, Jennifer

2022

Link zum Volltext

Verfügbarkeit prüfen

TP53 Mutation and Survival in Chronic Lymphocytic Leukemia

Journal of clinical oncology, 2010-10, Vol.28 (29), p.4473-4479

2010

Link zum Volltext

Verfügbarkeit prüfen

Opinion: What defines high-risk CLL in the post-chemoimmunotherapy era?

Frontiers in oncology, 2023-02, Vol.13, p.1106579-1106579

2023

Link zum Volltext

Verfügbarkeit prüfen

High-resolution genomic profiling of chronic lymphocytic leukemia reveals new recurrent genomic alterations

Blood, 2012-12, Vol.120 (24), p.4783-4794

2012

Link zum Volltext

Verfügbarkeit prüfen

Editorial: Biology and treatment of high-risk CLL

Frontiers in oncology, 2023-02, Vol.12, p.1109950-1109950

2023

Link zum Volltext

Verfügbarkeit prüfen

Rituximab and obinutuzumab differentially hijack the B cell receptor and NOTCH1 signaling pathways

iScience, 2021-02, Vol.24 (2), p.102089-102089, Article 102089

2021

Link zum Volltext

Verfügbarkeit prüfen

(Peri)Centromeric Rearrangements Are Recurrent Recombination Events in Complex-Karyotype Chronic Lymphocytic Leukemia

Blood, 2022-11, Vol.140 (Supplement 1), p.4115-4116

2022

Link zum Volltext

Verfügbarkeit prüfen

Monoallelic TP53 inactivation is associated with poor prognosis in chronic lymphocytic leukemia: results from a detailed genetic characterization with long-term follow-up

Blood, 2008-10, Vol.112 (8), p.3322-3329

2008

Link zum Volltext

Verfügbarkeit prüfen

Reduction of Mitochondrial Membrane Potential Leads to Enhancement of Type-II CD20-Antibody Cytotoxicity in Diffuse Large B-Cell Lymphoma

Blood, 2016-12, Vol.128 (22), p.1763-1763

2016

Link zum Volltext

Verfügbarkeit prüfen

Sustained Reduction of Intracellular Calcium Is Important to Maximise GA101-Mediated Direct Cell Death in B-Cell Lymphomas

Blood, 2017-12, Vol.130, p.1269-1269

2017

Link zum Volltext

Verfügbarkeit prüfen

NOTCH1, SF3B1, and TP53 mutations in fludarabine-refractory CLL patients treated with alemtuzumab: results from the CLL2H trial of the GCLLSG

Blood, 2013-08, Vol.122 (7), p.1266-1270

2013

Link zum Volltext

Verfügbarkeit prüfen

Rituximab and Obinutuzumab Induce Direct B-Cell Death Via B-Cell Receptor (BCR) Signaling, but Rituximab Elicits Stronger BCR-Derived Pro-Survival Signals Diminishing Apoptosis

Blood, 2019-11, Vol.134 (Supplement_1), p.1579-1579

2019

Link zum Volltext

Verfügbarkeit prüfen

Obinutuzumab for the treatment of indolent lymphoma

Future oncology (London, England), 2016-08, Vol.12 (15), p.1769-1781

2016

Link zum Volltext

Verfügbarkeit prüfen

Rituximab Activates NOTCH1 Signaling in CLL Cells and Induces Changes in the Cytokine Repertoire Favoring a Tumor-Protective Microenvironment

Blood, 2017-12, Vol.130, p.2996-2996

2017

Link zum Volltext

Verfügbarkeit prüfen

Anti-CD20 Monoclonal Antibodies Hijack the B-Cell Receptor Signaling Cascade Thereby Activating the NOTCH1 Signaling Pathway

Blood, 2018-11, Vol.132 (Supplement 1), p.588-588

2018

Link zum Volltext

Verfügbarkeit prüfen

Frequent evolution of copy number alterations in CLL following first-line treatment with FC(R) is enriched with TP53 alterations: results from the CLL8 trial

Leukemia, 2017-03, Vol.31 (3), p.734-738

2017

Link zum Volltext

Verfügbarkeit prüfen

Telomere length in poor-risk chronic lymphocytic leukemia: associations with disease characteristics and outcome

Leukemia & lymphoma, 2018-07, Vol.59 (7), p.1614-1623

2018

Link zum Volltext

Verfügbarkeit prüfen

Telomere dysfunction and chromothripsis

International journal of cancer, 2016-06, Vol.138 (12), p.2905-2914

2016

Link zum Volltext

Verfügbarkeit prüfen

In Chronic Lymphocytic Leukemia ΔCT7544-7545 Mutant NOTCH1 Maintains Transcription Factor Activity with Longer Lasting Effects Due to Slower Degradation

Blood, 2016-12, Vol.128 (22), p.971-971

2016

Link zum Volltext

Verfügbarkeit prüfen

High-Resolution SNP-Array Profiling of “Ultra-High Risk” CLL Cases Reveals New Recurrent Genomic Alterations

Blood, 2017-12, Vol.130, p.2992-2992

2017

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 72

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(69)
Mit Volltextzugriff
(68)

Publikationsform

Sprache

Englisch
(72)
Japanisch
(8)

Erscheinungsjahr

n.n

Thema

Science & Technology
(39)
Life Sciences & Biomedicine
(31)
Humans
(28)
Mutation
(13)
Leukemia, Lymphocytic, Chronic, B-Cell - Genetics
(12)
Oncology
(12)
Hematology
(11)
Male
(10)
Prognosis
(9)
Female
(8)
Tumor Suppressor Protein P53 - Genetics
(8)
Multidisciplinary Sciences
(7)
Science & Technology - Other Topics
(7)
Adult
(6)
Animals
(6)
Leukemia, Lymphocytic, Chronic, B-Cell - Drug Therapy
(6)
Mice
(6)
Treatment Outcome
(6)
University Students
(6)
Aged
(5)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

NOTCH1 Signalling: A key pathway for the development of high-risk chronic lymphocytic leukaemia

TP53 Mutation and Survival in Chronic Lymphocytic Leukemia

Opinion: What defines high-risk CLL in the post-chemoimmunotherapy era?

High-resolution genomic profiling of chronic lymphocytic leukemia reveals new recurrent genomic alterations

Editorial: Biology and treatment of high-risk CLL

High-resolution genomic profiling of adult and pediatric core-binding factor acute myeloid leukemia reveals new recurrent genomic alterations

Rituximab and obinutuzumab differentially hijack the B cell receptor and NOTCH1 signaling pathways

(Peri)Centromeric Rearrangements Are Recurrent Recombination Events in Complex-Karyotype Chronic Lymphocytic Leukemia

Mutations driving CLL and their evolution in progression and relapse

Gene mutations and treatment outcome in chronic lymphocytic leukemia: results from the CLL8 trial

Monoallelic TP53 inactivation is associated with poor prognosis in chronic lymphocytic leukemia: results from a detailed genetic characterization with long-term follow-up

Reduction of Mitochondrial Membrane Potential Leads to Enhancement of Type-II CD20-Antibody Cytotoxicity in Diffuse Large B-Cell Lymphoma

Sustained Reduction of Intracellular Calcium Is Important to Maximise GA101-Mediated Direct Cell Death in B-Cell Lymphomas

NOTCH1, SF3B1, and TP53 mutations in fludarabine-refractory CLL patients treated with alemtuzumab: results from the CLL2H trial of the GCLLSG

Rituximab and Obinutuzumab Induce Direct B-Cell Death Via B-Cell Receptor (BCR) Signaling, but Rituximab Elicits Stronger BCR-Derived Pro-Survival Signals Diminishing Apoptosis

Obinutuzumab for the treatment of indolent lymphoma

Rituximab Activates NOTCH1 Signaling in CLL Cells and Induces Changes in the Cytokine Repertoire Favoring a Tumor-Protective Microenvironment

Anti-CD20 Monoclonal Antibodies Hijack the B-Cell Receptor Signaling Cascade Thereby Activating the NOTCH1 Signaling Pathway

Genomic alterations in high-risk chronic lymphocytic leukemia frequently affect cell cycle key regulators and NOTCH1-regulated transcription

Multiplatform Profiling Characterizes Functional Networks in Genomically Stable and Instable Chronic Lymphocytic Leukemia

Frequent evolution of copy number alterations in CLL following first-line treatment with FC(R) is enriched with TP53 alterations: results from the CLL8 trial

Telomere length in poor-risk chronic lymphocytic leukemia: associations with disease characteristics and outcome

Telomere dysfunction and chromothripsis

In Chronic Lymphocytic Leukemia ΔCT7544-7545 Mutant NOTCH1 Maintains Transcription Factor Activity with Longer Lasting Effects Due to Slower Degradation

High-Resolution SNP-Array Profiling of “Ultra-High Risk” CLL Cases Reveals New Recurrent Genomic Alterations

Suchergebnisse filtern